<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35585374</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>25</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-7479</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics</Title><ISOAbbreviation>Neurotherapeutics</ISOAbbreviation></Journal><ArticleTitle>Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study.</ArticleTitle><Pagination><StartPage>1248</StartPage><EndPage>1258</EndPage><MedlinePgn>1248-1258</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s13311-022-01237-4</ELocationID><Abstract><AbstractText>Despite extensive research, amyotrophic lateral sclerosis (ALS) remains a progressive and invariably fatal neurodegenerative disease. Limited knowledge of the underlying causes of ALS has made it difficult to target upstream biological mechanisms of disease, and therapeutic interventions are usually administered relatively late in the course of disease. Genetic forms of ALS offer a unique opportunity for therapeutic development, as genetic associations may reveal potential insights into disease etiology. Genetic ALS may also be amenable to investigating earlier intervention given the possibility of identifying clinically presymptomatic, at-risk individuals with causative genetic variants. There is increasing evidence for a presymptomatic phase of ALS, with biomarker data from the Pre-Symptomatic Familial ALS (Pre-fALS) study showing that an elevation in blood neurofilament light chain (NfL) precedes phenoconversion to clinically manifest disease. Tofersen is an investigational antisense oligonucleotide designed to reduce synthesis of superoxide dismutase 1 (SOD1) protein through degradation of SOD1 mRNA. Informed by Pre-fALS and the tofersen clinical development program, the ATLAS study (NCT04856982) is designed to evaluate the impact of initiating tofersen in presymptomatic carriers of SOD1 variants associated with high or complete penetrance and rapid disease progression who also have biomarker evidence of disease activity (elevated plasma NfL). The ATLAS study will investigate whether tofersen can delay the emergence of clinically manifest ALS. To our knowledge, ATLAS is the first interventional trial in presymptomatic ALS and has the potential to yield important insights into the design and conduct of presymptomatic trials, identification, and monitoring of at-risk individuals, and future treatment paradigms in ALS.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Benatar</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Miami, 1120 NW 14th Street, Clinical Research Building, Miami, FL, 33136, USA. mbenatar@med.miami.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wuu</LastName><ForeName>Joanne</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Miami, 1120 NW 14th Street, Clinical Research Building, Miami, FL, 33136, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andersen</LastName><ForeName>Peter M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Department of Clinical Science, Neurosciences, Ume&#xe5; University, Ume&#xe5;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bucelli</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andrews</LastName><ForeName>Jinsy A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>The Neurological Institute, Columbia University Irving Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otto</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Martin Luther University, Halle-Wittenberg, Halle (Saale), Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farahany</LastName><ForeName>Nita A</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>Duke University School of Law, Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harrington</LastName><ForeName>Elizabeth A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Columbia University Irving Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Weiping</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Biogen, 225 Binney Street, Cambridge, MA, 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mitchell</LastName><ForeName>Adele A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Biogen, 225 Binney Street, Cambridge, MA, 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferguson</LastName><ForeName>Toby</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Biogen, 225 Binney Street, Cambridge, MA, 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chew</LastName><ForeName>Sheena</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Biogen, 225 Binney Street, Cambridge, MA, 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gedney</LastName><ForeName>Liz</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Biogen, 225 Binney Street, Cambridge, MA, 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oakley</LastName><ForeName>Sue</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Biogen, 225 Binney Street, Cambridge, MA, 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heo</LastName><ForeName>Jeong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Biogen, 225 Binney Street, Cambridge, MA, 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chary</LastName><ForeName>Sowmya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Biogen, 225 Binney Street, Cambridge, MA, 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fanning</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Biogen, 225 Binney Street, Cambridge, MA, 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graham</LastName><ForeName>Danielle</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Biogen, 225 Binney Street, Cambridge, MA, 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Peng</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Biogen, 225 Binney Street, Cambridge, MA, 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yingying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Biogen, 225 Binney Street, Cambridge, MA, 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Janice</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Biogen, 225 Binney Street, Cambridge, MA, 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fradette</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Biogen, 225 Binney Street, Cambridge, MA, 02142, USA. Stephanie.fradette@biogen.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04856982</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS105479</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurotherapeutics</MedlineTA><NlmUniqueID>101290381</NlmUniqueID><ISSNLinking>1878-7479</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical><Chemical><RegistryNumber>2NU6F9601K</RegistryNumber><NameOfSubstance UI="C000709090">tofersen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016376">Oligonucleotides, Antisense</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606290">SOD1 protein, human</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C531617">Amyotrophic lateral sclerosis 1</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neurotherapeutics. 2022 Jul;19(4):1246-1247</RefSource><PMID Version="1">35913611</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Neurotherapeutics. 2022 Sep 29;:</RefSource><PMID Version="1">36175782</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016376" MajorTopicYN="N">Oligonucleotides, Antisense</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Genetic testing</Keyword><Keyword MajorTopicYN="N">Neurofilament</Keyword><Keyword MajorTopicYN="N">Phenoconversion</Keyword><Keyword MajorTopicYN="N">Pre-fALS</Keyword><Keyword MajorTopicYN="N">SOD1-ALS</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>4</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>18</Day><Hour>23</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35585374</ArticleId><ArticleId IdType="pmc">PMC9587202</ArticleId><ArticleId IdType="doi">10.1007/s13311-022-01237-4</ArticleId><ArticleId IdType="pii">10.1007/s13311-022-01237-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377(9769):942&#x2013;955. doi: 10.1016/S0140-6736(10)61156-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(10)61156-7</ArticleId><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Galvin M, Ryan P, Maguire S, Heverin M, Madden C, Vajda A, et al. The path to specialist multidisciplinary care in amyotrophic lateral sclerosis: a population- based study of consultations, interventions and costs. PLoS One. 2017;12(6):e0179796.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5480998</ArticleId><ArticleId IdType="pubmed">28640860</ArticleId></ArticleIdList></Reference><Reference><Citation>Nzwalo H, de Abreu D, Swash M, Pinto S, de Carvalho M. Delayed diagnosis in ALS: the problem continues. J Neurol Sci. 2014;343(1&#x2013;2):173&#x2013;175. doi: 10.1016/j.jns.2014.06.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2014.06.003</ArticleId><ArticleId IdType="pubmed">24972820</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams JR, Fitzhenry D, Grant L, Martyn D, Kerr DA. Diagnosis pathway for patients with amyotrophic lateral sclerosis: retrospective analysis of the US Medicare longitudinal claims database. BMC Neurol. 2013;13(1):160. doi: 10.1186/1471-2377-13-160.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2377-13-160</ArticleId><ArticleId IdType="pmc">PMC4029731</ArticleId><ArticleId IdType="pubmed">24499173</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Turner MR, Wuu J. Defining pre-symptomatic amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(5&#x2013;6):303&#x2013;309. doi: 10.1080/21678421.2019.1587634.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1587634</ArticleId><ArticleId IdType="pmc">PMC6613999</ArticleId><ArticleId IdType="pubmed">30892087</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vivo DC, Bertini E, Swoboda KJ, Hwu WL, Crawford TO, Finkel RS, et al; Nurture Study Group. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the phase 2 NURTURE study. Neuromuscul Disord. 2019;29(11):842&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7127286</ArticleId><ArticleId IdType="pubmed">31704158</ArticleId></ArticleIdList></Reference><Reference><Citation>Logroscino G, Traynor BJ, Hardiman O, Chi&#xf2; A, Mitchell D, Swingler RJ, et al. Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry. 2010;81(4):385&#x2013;390. doi: 10.1136/jnnp.2009.183525.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2009.183525</ArticleId><ArticleId IdType="pmc">PMC2850819</ArticleId><ArticleId IdType="pubmed">19710046</ArticleId></ArticleIdList></Reference><Reference><Citation>Bunton-Stasyshyn RK, Saccon RA, Fratta P, Fisher EM. SOD1 function and its implications for amyotrophic lateral sclerosis pathology: new and renascent themes. Neuroscientist. 2015;21(5):519&#x2013;529. doi: 10.1177/1073858414561795.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1073858414561795</ArticleId><ArticleId IdType="pubmed">25492944</ArticleId></ArticleIdList></Reference><Reference><Citation>Amyotrophic Lateral Sclerosis online Database. SOD1 gene summary. Available at: https://alsod.ac.uk/output/gene.php/SOD1. Accessed 22 July&#xa0;2021.</Citation></Reference><Reference><Citation>Bali T, Self W, Liu J, Siddique T, Wang LH, Bird TD, et al. Defining SOD1 ALS natural history to guide therapeutic clinical trial design. J Neurol Neurosurg Psychiatry. 2017;88(2):99&#x2013;105. doi: 10.1136/jnnp-2016-313521.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2016-313521</ArticleId><ArticleId IdType="pmc">PMC5136332</ArticleId><ArticleId IdType="pubmed">27261500</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz ME, McKenna-Yasek D, Sapp PE, Chin W, Geller B, Hayden DL, et al. Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis. Ann Neurol. 1997;41(2):210&#x2013;221. doi: 10.1002/ana.410410212.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410410212</ArticleId><ArticleId IdType="pubmed">9029070</ArticleId></ArticleIdList></Reference><Reference><Citation>Li HF, Wu ZY. Genotype-phenotype correlations of amyotrophic lateral sclerosis. Transl Neurodegener. 2016;5:3. doi: 10.1186/s40035-016-0050-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-016-0050-8</ArticleId><ArticleId IdType="pmc">PMC4738789</ArticleId><ArticleId IdType="pubmed">26843957</ArticleId></ArticleIdList></Reference><Reference><Citation>Prudencio M, Hart PJ, Borchelt DR, Andersen PM. Variation in aggregation propensities among ALS-associated variants of SOD1: correlation to human disease. Hum Mol Genet. 2009;18(17):3217&#x2013;3226. doi: 10.1093/hmg/ddp260.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddp260</ArticleId><ArticleId IdType="pmc">PMC2722984</ArticleId><ArticleId IdType="pubmed">19483195</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashita S, Ando Y. Genotype-phenotype relationship in hereditary amyotrophic lateral sclerosis. Transl Neurodegener. 2015;4:13. doi: 10.1186/s40035-015-0036-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-015-0036-y</ArticleId><ArticleId IdType="pmc">PMC4513711</ArticleId><ArticleId IdType="pubmed">26213621</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilieva H, Polymenidou M, Cleveland DW. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J Cell Biol. 2009;187(6):761&#x2013;772. doi: 10.1083/jcb.200908164.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200908164</ArticleId><ArticleId IdType="pmc">PMC2806318</ArticleId><ArticleId IdType="pubmed">19951898</ArticleId></ArticleIdList></Reference><Reference><Citation>McCampbell A, Cole T, Wegener AJ, Tomassy GS, Setnicka A, Farley BJ, et al. Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models. J Clin Invest. 2018;128(8):3558&#x2013;3567. doi: 10.1172/JCI99081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI99081</ArticleId><ArticleId IdType="pmc">PMC6063493</ArticleId><ArticleId IdType="pubmed">30010620</ArticleId></ArticleIdList></Reference><Reference><Citation>Saccon RA, Bunton-Stasyshyn RK, Fisher EMC, Fratta P. Is SOD1 loss of function involved in amyotrophic lateral sclerosis? Brain. 2013;136(Pt 8):2342&#x2013;2358. doi: 10.1093/brain/awt097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awt097</ArticleId><ArticleId IdType="pmc">PMC3722346</ArticleId><ArticleId IdType="pubmed">23687121</ArticleId></ArticleIdList></Reference><Reference><Citation>Sau D, De Biasi S, Vitellaro-Zuccarello L, Riso P, Guarnieri S, Porrini M, et al. Mutation of SOD1 in ALS: a gain of a loss of function. Hum Mol Genet. 2007;16(13):1604&#x2013;1618. doi: 10.1093/hmg/ddm110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddm110</ArticleId><ArticleId IdType="pubmed">17504823</ArticleId></ArticleIdList></Reference><Reference><Citation>Ekhtiari Bidhendi E, Bergh J, Zetterstr&#xf6;m P, Forsberg K, Pakkenberg B, Andersen PM, et al. Mutant superoxide dismutase aggregates from human spinal cord transmit amyotrophic lateral sclerosis. Acta Neuropathol. 2018;136(6):939&#x2013;953. doi: 10.1007/s00401-018-1915-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1915-y</ArticleId><ArticleId IdType="pmc">PMC6280858</ArticleId><ArticleId IdType="pubmed">30284034</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett CF, Krainer AR, Cleveland DW. Antisense oligonucleotide therapies for neurodegenerative diseases. Annu Rev Neurosci. 2019;42:385&#x2013;406. doi: 10.1146/annurev-neuro-070918-050501.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-neuro-070918-050501</ArticleId><ArticleId IdType="pmc">PMC7427431</ArticleId><ArticleId IdType="pubmed">31283897</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen X, Corey DR. Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs. Nucleic Acids Res. 2018;46(4):1584&#x2013;1600. doi: 10.1093/nar/gkx1239.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkx1239</ArticleId><ArticleId IdType="pmc">PMC5829639</ArticleId><ArticleId IdType="pubmed">29240946</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T, Cudkowicz M, Shaw PJ, Andersen PM, Atassi N, Bucelli RC, et al. Phase 1&#x2013;2 trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2020;383(2):109&#x2013;119. doi: 10.1056/NEJMoa2003715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2003715</ArticleId><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T, Cudkowicz M. In American Neurological Association Annual Meeting (Virtual, 2021 Oct 17&#x2013;19).</Citation></Reference><Reference><Citation>Benatar M, Wuu J, McHutchison C, Postuma RB, Boeve BF, Petersen R, et al. Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases. Brain. 2022;145(1):27&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8967095</ArticleId><ArticleId IdType="pubmed">34677606</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Wuu J. Presymptomatic studies in ALS: rationale, challenges, and approach. Neurology. 2012;79(16):1732&#x2013;1739. doi: 10.1212/WNL.0b013e31826e9b1d.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31826e9b1d</ArticleId><ArticleId IdType="pmc">PMC3468777</ArticleId><ArticleId IdType="pubmed">23071166</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Wuu J, Lombardi V, Jeromin A, Bowser R, Andersen PM, et al. Neurofilaments in pre-symptomatic ALS and the impact of genotype. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(7&#x2013;8):538&#x2013;548. doi: 10.1080/21678421.2019.1646769.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1646769</ArticleId><ArticleId IdType="pmc">PMC6768722</ArticleId><ArticleId IdType="pubmed">31432691</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Wuu J, Andersen PM, Lombardi V, Malaspina A. Neurofilament light: a candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Ann Neurol. 2018;84(1):130&#x2013;139. doi: 10.1002/ana.25276.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25276</ArticleId><ArticleId IdType="pubmed">30014505</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeffreys H. Theory of Probablility. Oxford Classic Texts in the Physical Sciences.&#xa0;1939.</Citation></Reference><Reference><Citation>Fanos JH, Gronka S, Wuu J, Stanislaw C, Andersen PM, Benatar M. Impact of presymptomatic genetic testing for familial amyotrophic lateral sclerosis. Genet Med. 2011;13(4):342&#x2013;348. doi: 10.1097/GIM.0b013e318204d004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/GIM.0b013e318204d004</ArticleId><ArticleId IdType="pmc">PMC4039017</ArticleId><ArticleId IdType="pubmed">21285887</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Stanislaw C, Reyes E, Hussain S, Cooley A, Fernandez MC, et al. Presymptomatic ALS genetic counseling and testing: experience and recommendations. Neurology. 2016;86(24):2295&#x2013;2302. doi: 10.1212/WNL.0000000000002773.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002773</ArticleId><ArticleId IdType="pmc">PMC4909562</ArticleId><ArticleId IdType="pubmed">27194384</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts JS, Patterson AK, Uhlmann WR. Genetic testing for neurodegenerative diseases: ethical and health communication challenges. Neurobiol Dis. 2020;141:104871.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7311284</ArticleId><ArticleId IdType="pubmed">32302673</ArticleId></ArticleIdList></Reference><Reference><Citation>Abacan M, Alsubaie L, Barlow-Stewart K, Caanen B, Cordier C, Courtney E, et al. The global state of the genetic counseling profession. Eur J Hum Genet. 2019;27(2):183&#x2013;197. doi: 10.1038/s41431-018-0252-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41431-018-0252-x</ArticleId><ArticleId IdType="pmc">PMC6336871</ArticleId><ArticleId IdType="pubmed">30291341</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Battistini S, Calvo A, Caponnetto C, Conforti FL, Corbo M, et al; ITALSGEN Consortium. Genetic counselling in ALS: facts, uncertainties and clinical suggestions. J Neurol Neurosurg Psychiatry. 2014;85(5):478&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">23833266</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanos JH, Gelinas DF, Miller RG. &#x201c;You have shown me my end&#x201d;: attitudes toward presymptomatic testing for familial amyotrophic lateral sclerosis. Am J Med Genet A. 2004;129A(3):248&#x2013;253. doi: 10.1002/ajmg.a.30178.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajmg.a.30178</ArticleId><ArticleId IdType="pubmed">15326623</ArticleId></ArticleIdList></Reference><Reference><Citation>US Food and Drug Administration. Rare diseases: natural history studies for drug development. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/rare-diseases-natural-history-studies-drug-development. Accessed 30 Nov&#xa0;2021.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>